MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
AVEO Pharmaceuticals Cash Conversion Cycle 2011-2026 | AVEO
Annual Cash Conversion Cycle AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -123 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -123 | -123 | -123 |
Quarterly Cash Conversion Cycle AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -17.2 | - | 5.09 | -59.3 | -141 | -363 | -2.4 K | - | 2.76 | 5.49 | 6.45 | 195 | 5.79 | 212 | 132 | 186 | 112 | 638 | 152 | 447 | 7.95 | 105 | 25.8 | 738 | 94.5 | 486 | 215 | 118 | 27.9 | 3.16 K | 2.38 K | 1.86 K | 245 | 116 | 9.92 | 278 | 278 | 277 | 3.06 K | 121 | 1.85 K | 1 K | 1.48 K | 600 | 184 | 24.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.16 K | -2.4 K | 406 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 21.54 | 0.84 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
-1.67 K | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.53 | 3.74 % | $ 393 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.21 | 0.48 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 25.19 | 4.42 % | $ 3.21 B | USA |
 |
Chimerix
CMRX
|
588 | - | - | $ 756 M | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 33.26 | 2.04 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.51 | 2.38 % | $ 402 M | Britain |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |
 |
CTI BioPharma Corp.
CTIC
|
-216 | - | - | $ 1.2 B | USA |